Martin Bergstrand, Ph.D.

Principal Consultant & MIDD Platform Scientific Lead

Bio

  • Co-founded Pharmetheus in 2012, actively working in client projects and with continuous improvements.
  • Expertise includes trial design, pharmacometrics (especially complex pharmacokinetics, mechanism based PKPD and Markov models), and model informed drug development in therapeutic areas such as infectious, metabolic, and cardiovascular diseases.
  • Experience as part-time Researcher at Uppsala University, Sweden, where he performed pharmacometric research primarily by supervision of Ph.D. students. Previously, he worked as Visiting Scientist at Mahidol-Oxford Tropical Medicine Research Unit, Thailand, and Clinical Pharmacology Scientist at AstraZeneca R&D Mölndal, Sweden.
  • M.Sc. in Biomedicine (2003) from University of Kalmar, Sweden, and Ph.D. in Pharmaceutical Biosciences (2011) from Uppsala University, Sweden.
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Towards Industrialisation of Probability of Pharmacological Success (PoPS)Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modelingApplication relevant shrinkage metricsCaplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura [2]Pharmacokinetic Modeling and Simulation Support for Age‐ and Weight‐Adjusted Dosing of Dabigatran Etexilate in Children with Venous ThromboembolismCaplacizumab Model-Based Dosing Recommendations In Pediatric Patients With Acquired Thrombotic Thrombocytopenic PurpuraModel-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in HumansCaplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD ModellingEffect of Plasma Exchange on the Pharmacokinetics and Pharmacodynamics of Caplacizumab, PS1487Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients with Acquired Thrombotic Thrombocytopenic Purpura, PB2249An Automated Sampling Importance Resampling Procedure for Estimating Parameter Uncertainty